MS

Michael Shih

Chief Executive Officer

NeoPhore Ltd

New York, New York


Contact Information

Email
Unlock
LinkedIn

Company Information

Company
NeoPhore Ltd
Industry
research
Employees
21.0
Seniority
C suite
Annual Revenue
1200000.0
Total Funding
45939394.0
Latest Funding
Series B

Technologies

Outlook Typekit reCAPTCHA Apache Mobile Friendly Google Analytics Google Tag Manager Render SharePoint Python Barracuda MSP Flutter

Keywords

biotechnology drug discovery small molecule therapeutics oncology immunooncology cancer genetics translational medicine biotechnology research cancer therapy neoantigen small molecule drugs immuno-oncology dna mismatch repair mmr pathway cancer immunotherapy neoantigen creation tumor immunogenicity checkpoint inhibitors cancer biomarkers solid tumors treatment personalized therapy preclinical studies biopharmaceuticals immune response modulation clinical validation tumor microenvironment cancer cell biology biotech innovation tumor genotype alteration cancer treatment outcomes microsatellite instability therapeutic targets biotech fundraising drug development treatment efficacy immunotherapy resistance novel therapeutic agents tmb increase cancer research oncological therapies precision medicine cancer immune evasion neoantigen diversity immunotherapeutic strategies cancer target identification vaccine development tumor-associated antigens biomedical engineering biological therapies cancer cell signaling pharmaceutical development therapeutic pipelines cancer metastasis peer-reviewed research scientific partnerships patient outcomes hospital & health care

Get Full Contact Details

Subscribe to reveal email addresses and export contacts.

View Plans